m+Medelevator.RU
← Поиск публикаций
Bioorganic & medicinal chemistry letters · 2025

Rational design and translational advancement of phospholipid-based nanocarriers for targeted cancer therapy.

Источник пометил эту публикацию как отозванную.
СтатьяОбзорОтозванная публикацияНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Doroshenko Kateryna Mykhailivna, Shefchenko Oleksander Ivanovich

Аннотация

Phospholipid-derived nanocarriers represent a versatile and chemically customizable class of drug delivery systems that self-assemble into bilayered vesicles due to their intrinsic amphiphilicity. These systems can encapsulate both hydrophilic and hydrophobic drugs through non-covalent interactions and manipulation of lipid phase behavior. This review examines the molecular and supramolecular principles underlying the formation, stability, and functional performance of key phospholipid-based nanocarriers-including liposomes, transferosomes, ethosomes, invasomes, phytosomes, pharmacosomes, and virosomes. We analyze critical structural parameters such as bilayer packing, surface charge, curvature elasticity, and membrane permeability, emphasizing their impact on drug loading efficiency, controlled release, and bioavailability. Advanced multilamellar systems such as vesosomes and spongosomes are also highlighted for their promise in achieving site-specific, sustained drug delivery. Key fabrication methods-including thin-film hydration, ethanol injection, freeze-thaw cycles, and microfluidics-are discussed alongside analytical techniques such as dynamic light scattering (DLS), differential scanning calorimetry (DSC), Fourier-transform infrared spectroscopy (FTIR), and cryo-transmission electron microscopy (cryo-TEM). The review further explores the translational landscape, with a focus on clinically approved liposomal formulations, patent developments, and emerging clinical trials involving stimuli-responsive systems. Persistent challenges such as colloidal stability, tumor penetration, immune system interactions, and scalable manufacturing are critically assessed. Altogether, this review offers a chemistry-focused framework for the rational design and clinical translation of phospholipid nanocarriers in cancer drug delivery.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты